Elena Olivieri

Mrs. Elena Olivieri

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

6 February 2026 in Nanomaterials
Verified
Journal Article
Open access
PDF file
EOElena Olivieri
Elena Olivieri
SASimone Amatori
Simone Amatori
CBChiara Battocchio
Chiara Battocchio
GIGiovanna Iucci
Giovanna Iucci
Martina MarsottoMartina Marsotto
Martina Marsotto
Iole VendittiIole Venditti
Iole Venditti
Gold nanorods (AuNRs) were synthesized and optimized with the aim of obtaining strongly hydrophilic nanomaterials, suitable as a drug delivery system (DDS) for copper-based drugs. After careful purification, AuNRs were characterized by ultraviolet–visible–near-infrared spectroscopy (UV–Vis–NIR), showing two typical localized surface plasmon resonance (LSPR) bands in the range 550–750 nm. Fourier Transform Infrared (FT-IR) and high-resolution X-ray photoelectron (HR-XPS) spectroscopies verified the surface functionalization. Transmission electron microscopy (TEM) showed AuNRs with regular shape and size, with an aspect ratio (AR) of 2.6. Dynamic Light Scattering (DLS) measurements confirmed the size and the stability in water for up to 3 months. The AuNRs were conjugated with copper(I) drugs, i.e., [Cu(PTA)4]BF4 (PTA = 1,3,5-triaza-7-phosphadamantane). The drug loading procedures and efficiency were optimized, and the best loading was η (%) = 50 ± 7%. The non-covalent interactions of the Cu(I) complex with the AuNRs were studied by means of UV–Vis–NIR, ζ-potential, HR-TEM, FT-IR, synchrotron radiation-induced X-ray photoelectron (SR-XPS), and near-edge X-ray absorption fine structure (NEXAFS) spectroscopy measurements. The MTT assay performed on Vero E6 cells showed that AuNRs and AuNR-Cu(I) conjugates had no significant effect on cell viability, being biocompatible, causing a reduction in cell viability only after prolonged exposure.

18 June 2026 in Annals of Neurology
Verified
Journal Article
Open access
MPMarta Pirronello
Marta Pirronello
MPMario Picozza
Mario Picozza
GGGisella Guerrera
Gisella Guerrera
SCSilvia Corbisiero
Silvia Corbisiero
AMAndrea Misiti
Andrea Misiti
LBLuca Battistini
Luca Battistini
Objective: Multiple sclerosis (MS) is a chronic autoimmune disease where B cells play a central pathogenic role. Cladribine, an oral therapy, provides durable benefits by reshaping lymphocyte populations, yet its specific long‐term impact on distinct B‐cell subsets is not fully understood. This study aimed to define cladribine's longitudinal effects on B‐cell subsets and characterize their inflammatory properties. Methods: We conducted a 48‐month longitudinal study of 36 persons with relapsing–remitting MS treated with cladribine who had completed 2 annual treatment cycles, using high‐parameter flow cytometry to track B‐cell subset dynamics. In a parallel cross‐sectional analysis, B cells from 16 untreated patients and 16 healthy donors were profiled for polyfunctional cytokine production granulocyte‐macrophage colony stimulating factor (GM‐CSF), interleukin‐6 (IL‐6), tumor necrosis factor‐α (TNF‐α) and key surface markers. Results: Cladribine induced profound, sustained depletion of memory B cells, with marginal zone‐like (MZ‐like) cells showing the deepest and most persistent loss, alongside reconstitution of transitional and naïve populations. Functionally, MZ‐like B cells were the most potent polyfunctional producers of proinflammatory cytokines and immunoglobulin M (IgM), a capacity significantly enhanced in persons with MS compared to healthy donors, and expressed the highest levels of CD1c and CD1d, consistent with specialization in lipid antigen presentation. Interpretation: MZ‐like B cells are a dominant, polyfunctional inflammatory subset in MS, equipped for non‐canonical lipid antigen presentation and IgM secretion. They represent a preferential pharmacological target of cladribine. Sustained reduction of this pathogenic memory pool, followed by repopulation with less inflammatory B cells, offers a mechanistic basis for cladribine's durable clinical benefit and nominates MZ‐like cells as biomarkers of response and therapeutic targets. ANN NEUROL 2026